Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial
M. Sekiya, T. Kawayama, Y. Fukuchi, Y. Takahashi, T. Kaiso, K. Ikeda, T. Overend, D. Banerji (Tokyo, Fukuoka, Japan; Horsham, United Kingdom; East Hanover, United States Of America)
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Session: COPD treatments: efficacy and safety
Session type: Thematic Poster Session
Number: 2103
Disease area: Airway diseases
Abstract Introduction: NVA237 (glycopyrronium bromide) is a once-daily (QD) inhaled long-acting muscarinic antagonist for the maintenance treatment of COPD.Methods: The primary objective of the 52-week, multi-center, randomized, open label, parallel group GLycopyrronium bromide in COPD airWays clinical study 4 (GLOW4) was to assess the safety and tolerability of NVA237 50µg QD for 52 wks in Japanese patients with moderate-to-severe COPD. A secondary objective was to compare the safety and efficacy of NVA237 to open-label tiotropium 18 μg QD (TIO).Results: 163 patients were randomized (NVA237=123, TIO=40); 84% completed. Mean age was 68.7 yrs, 97.5% male. Overall adverse events (AE) incidence was similar between NVA237 and TIO. The only AEs with >10% incidence in any group were COPD worsening (24.4 and 32.5%) and nasopharyngitis (30.9 and 32.5%) for NVA237 and TIO, respectively. Serious AEs occurred in 13 and 15% patients for NVA237 and TIO, respectively, with no deaths. There were no reports of notable pulse rate (>130 bpm, or ≥120 and +15 bpm from baseline) and QTc interval (Fridericia) >500ms over 52 wks. Dry mouth incidence was less frequent with NVA237 (1.6%) vs TIO (5%). A clinically significant increase from baseline in pre-dose FEV1 was observed for NVA (101 mL) and TIO (173 mL) at Wk 12. The event-free rate for moderate or severe COPD exacerbation was 78.9% for NVA237 and 76.6% for TIO at Wk 52.Conclusion: NVA237 once daily had a safety and tolerability and efficacy profile similar to tiotropium in Japanese patients with moderate-to-severe COPD over 52 weeks.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Sekiya, T. Kawayama, Y. Fukuchi, Y. Takahashi, T. Kaiso, K. Ikeda, T. Overend, D. Banerji (Tokyo, Fukuoka, Japan; Horsham, United Kingdom; East Hanover, United States Of America). Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial. Eur Respir J 2012; 40: Suppl. 56, 2103
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009
Safety and pharmacokinetics of nintedanib plus sildenafil in the INSTAGE trial Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019
Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021
Safety and tolerability of indacaterol over 52 weeks of treatment in COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021
Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2 -agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Late-breaking abstract: Once-daily NVA237 improves exercise endurance from first dose in patients with COPD: The GLOW3 trial Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011
Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Indacaterol once-daily provides superior efficacy to salmeterol: A 12-week trial Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Safety profile of tiotropium add-on therapy in paediatric patients by gender Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013